

Johnson & Johnson
Third Quarter 2026
Other Financial Disclosures
Table of Contents

<u>Table 1: Sales by Segment</u>	1
<u>Table 2: Sales by Geographic Area</u>	2
<u>Table 3: Sales of Key Products/Franchises</u>	3 - 7
<u>Table 4: Condensed Consolidated Statement of Earnings - QTD</u>	8
<u>Table 5: Condensed Consolidated Statement of Earnings - YTD</u>	9
<u>Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD</u>	10
<u>Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD</u>	11
<u>Table 8: Non-GAAP Adjusted Net Earnings</u>	12
<u>Table 9: Non-GAAP P&L by Segment Reconciliation 2026 - QTD</u>	13
<u>Table 10: Non-GAAP P&L by Segment Reconciliation 2025 - QTD</u>	14
<u>Table 11: Non-GAAP P&L by Segment Reconciliation 2026 - YTD</u>	15
<u>Table 12: Non-GAAP P&L by Segment Reconciliation 2025 - YTD</u>	16

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

		Percent Change				
	2026	2025	Total	Operations	Currency	
Sales to customers by segment of business						
Innovative Medicine						
U.S.	\$ 10,447	9,402	11.1 %	11.1	-	
International	6,310	6,161	2.4	3.0	(0.6)	
	16,757	15,563	7.7	7.9	(0.2)	
MedTech						
U.S.	4,512	4,306	4.8	4.8	-	
International	4,130	4,124	0.1	0.1	0.0	
	8,642	8,430	2.5	2.5	0.0	
U.S.	14,959	13,708	9.1	9.1	-	
International	10,440	10,285	1.5	1.8	(0.3)	
Worldwide	\$ 25,399	23,993	5.9 %	6.0	(0.1)	

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

NINE MONTHS

		Percent Change				
	2026	2025	Total	Operations	Currency	
	\$ 29,297	26,655	9.9 %	9.9	-	
	19,270	17,983	7.2	3.6	3.6	
	48,567	44,638	8.8	7.4	1.4	
	13,525	12,902	4.8	4.8	-	
	12,679	12,089	4.9	2.2	2.7	
	26,204	24,991	4.9	3.5	1.4	
	42,822	39,557	8.3	8.3	-	
	31,949	30,072	6.2	3.0	3.2	
	\$ 74,771	69,629	7.4 %	6.0	1.4	

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)					
THIRD QUARTER					
			Percent Change		
	2026	2025	Total	Operational	Currency
Sales to customers by geographic area					
U.S.	\$ 14,959	13,708	9.1 %	9.1	-
Europe	5,405	5,440	(0.6)	1.0	(1.6)
Western Hemisphere excluding U.S.	1,385	1,231	12.5	8.0	4.5
Asia-Pacific, Africa	3,650	3,614	1.0	1.0	0.0
International	10,440	10,285	1.5	1.8	(0.3)
Worldwide	\$ 25,399	23,993	5.9 %	6.0	(0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

NINE MONTHS					
			Percent Change		
	2026	2025	Total	Operational	Currency
\$ 42,822	39,557	8.3 %	8.3	-	
16,979	15,937	6.5	2.3	4.2	
3,987	3,604	10.6	4.5	6.1	
10,983	10,531	4.3	3.6	0.7	
31,949	30,072	6.2	3.0	3.2	
\$ 74,771	69,629	7.4 %	6.0	1.4	

INNOVATIVE MEDICINE SEGMENT ⁽²⁾

ONCOLOGY

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
THIRD QUARTER					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 4,267	3,468	23.0%	23.0%	-
Intl	3,335	3,060	9.0%	9.5%	(0.5)%
WW	7,602	6,529	16.4%	16.7%	(0.3)%
DARZALEX					
US	2,528	2,088	21.1%	21.1%	-
Intl	1,711	1,584	8.0%	8.5%	(0.5)%
WW	4,239	3,672	15.4%	15.6%	(0.2)%
CARVYKTI					
US	472	396	19.4%	19.4%	-
Intl	238	128	85.3%	84.1%	1.2%
WW	710	524	35.5%	35.2%	0.3%
TECVAYLI					
US	236	115	*	*	-
Intl	77	62	24.0%	25.9%	(1.9)%
WW	312	177	76.6%	77.3%	(0.7)%
TALVEY					
US	112	85	31.6%	31.6%	-
Intl	59	37	62.9%	66.9%	(4.0)%
WW	171	122	40.9%	42.1%	(1.2)%
RYBREVA NT / LAZCLUZE					
US	201	136	47.9%	47.9%	-
Intl	119	61	94.5%	98.3%	(3.8)%
WW	320	198	62.3%	63.5%	(1.2)%
ERLEADA					
US	423	378	11.8%	11.8%	-
Intl	600	558	7.7%	7.7%	0.0%
WW	1,023	936	9.4%	9.4%	0.0%
IMBRUVICA					
US	145	211	(31.6)%	(31.6)%	-
Intl	420	483	(13.2)%	(12.6)%	(0.6)%
WW	563	695	(18.8)%	(18.4)%	(0.4)%
OTHER ONCOLOGY ⁽³⁾					
US	149	61	*	*	-
Intl	111	147	(24.4)%	(23.9)%	(0.5)%
WW	262	207	26.3%	26.7%	(0.4)%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

NINE MONTHS					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 11,951	9,866	21.1%	21.1%	-
Intl	10,030	8,652	15.9%	11.9%	4.0%
WW	21,981	18,519	18.7%	16.8%	1.9%
DARZALEX					
US	7,171	5,934	20.9%	20.9%	-
Intl	5,239	4,514	16.1%	11.9%	4.2%
WW	12,410	10,448	18.8%	17.0%	1.8%
CARVYKTI					
US	1,377	1,072	28.5%	28.5%	-
Intl	587	260	*	*	*
WW	1,964	1,332	47.4%	45.5%	1.9%
TECVAYLI					
US	549	334	64.4%	64.4%	-
Intl	225	160	40.6%	37.7%	2.9%
WW	774	494	56.7%	55.7%	1.0%
TALVEY					
US	325	235	38.1%	38.1%	-
Intl	172	79	*	*	*
WW	497	314	58.3%	57.5%	0.8%
RYBREVA NT / LAZCLUZE					
US	566	388	46.1%	46.1%	-
Intl	300	130	*	*	*
WW	866	518	67.4%	67.5%	(0.1)%
ERLEADA					
US	1,161	1,048	10.8%	10.8%	-
Intl	1,806	1,567	15.3%	10.8%	4.5%
WW	2,967	2,615	13.5%	10.8%	2.7%
IMBRUVICA					
US	437	685	(36.3)%	(36.3)%	-
Intl	1,386	1,453	(4.7)%	(8.7)%	4.0%
WW	1,822	2,139	(14.8)%	(17.5)%	2.7%
OTHER ONCOLOGY ⁽³⁾					
US	365	171	*	*	-
Intl	314	488	(35.7)%	(36.0)%	0.3%
WW	680	659	3.2%	2.9%	0.3%

See footnotes at end of schedule

IMMUNOLOGY

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
THIRD QUARTER					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 2,804	2,676	4.8%	4.8%	-
Intl	1,417	1,493	(5.1)%	(4.8)%	(0.3)%
WW	4,221	4,168	1.3%	1.4%	(0.1)%
TREMFYA					
US	1,772	989	79.1%	79.1%	-
Intl	624	434	43.7%	43.4%	0.3%
WW	2,396	1,424	68.3%	68.2%	0.1%
SIMPONI / SIMPONI ARIA					
US	269	309	(13.2)%	(13.2)%	-
Intl	299	377	(20.6)%	(20.3)%	(0.3)%
WW	568	687	(17.3)%	(17.1)%	(0.2)%
REMICADE					
US	258	326	(20.8)%	(20.8)%	-
US Exports ⁽⁴⁾	12	19	(37.1)%	(37.1)%	-
Intl	124	132	(6.2)%	(7.5)%	1.3%
WW	394	476	(17.3)%	(17.6)%	0.3%
STELARA					
US	368	1,022	(64.0)%	(64.0)%	-
Intl	349	549	(36.5)%	(35.5)%	(1.0)%
WW	716	1,570	(54.4)%	(54.0)%	(0.4)%
OTHER IMMUNOLOGY					
US	126	12	*	*	-
Intl	21	0	*	*	*
WW	147	12	*	*	*
NEUROSCIENCE					
US	1,733	1,367	26.8%	26.8%	-
Intl	642	658	(2.4)%	(1.7)%	(0.7)%
WW	2,375	2,024	17.3%	17.6%	(0.3)%
SPRAVATO					
US	559	405	37.9%	37.9%	-
Intl	66	53	22.7%	21.4%	1.3%
WW	624	459	36.1%	36.0%	0.1%
CAPLYTA ⁽⁵⁾					
US	398	240	66.1%	66.1%	-
Intl	-	-	-	-	-
WW	398	240	66.1%	66.1%	-
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA					
US	739	664	11.4%	11.4%	-
Intl	258	267	(3.0)%	(2.4)%	(0.6)%
WW	998	929	7.3%	7.5%	(0.2)%
CONCERTA / Methylphenidate					
US	6	14	(56.3)%	(56.3)%	-
Intl	138	127	8.1%	8.9%	(0.8)%
WW	143	140	2.1%	2.9%	(0.8)%
OTHER NEUROSCIENCE					
US	32	46	(30.6)%	(30.6)%	-
Intl	180	210	(14.3)%	(13.1)%	(1.2)%
WW	212	256	(17.3)%	(16.2)%	(1.1)%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
NINE MONTHS					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 7,031	7,377	(4.7)%	(4.7)%	-
Intl	4,414	4,492	(1.7)%	(4.9)%	3.2%
WW	11,445	11,868	(3.6)%	(4.8)%	1.2%
US	4,279	2,384	79.5%	79.5%	-
Intl	1,771	1,181	49.9%	44.7%	5.2%
WW	6,050	3,566	69.7%	67.9%	1.8%
US	798	906	(11.9)%	(11.9)%	-
Intl	1,035	1,130	(8.4)%	(11.4)%	3.0%
WW	1,833	2,036	(10.0)%	(11.6)%	1.6%
US	742	923	(19.6)%	(19.6)%	-
US Exports ⁽⁴⁾	40	63	(36.6)%	(36.6)%	-
Intl	372	413	(9.8)%	(12.9)%	3.1%
WW	1,154	1,398	(17.5)%	(18.4)%	0.9%
US	924	3,081	(70.0)%	(70.0)%	-
Intl	1,188	1,768	(32.8)%	(34.9)%	2.1%
WW	2,112	4,848	(56.4)%	(57.2)%	0.8%
US	249	21	*	*	-
Intl	48	0	*	*	*
WW	297	21	*	*	*
US	4,886	3,712	31.6%	31.6%	-
Intl	2,001	2,011	(0.5)%	(3.0)%	2.5%
WW	6,887	5,722	20.3%	19.5%	0.8%
US	1,479	1,047	41.3%	41.3%	-
Intl	197	146	34.8%	28.1%	6.7%
WW	1,676	1,193	40.5%	39.7%	0.8%
US	1,029	451	*	*	-
Intl	-	-	-	-	-
WW	1,029	451	*	*	-
US	2,235	2,021	10.6%	10.6%	-
Intl	816	804	1.5%	(0.8)%	2.3%
WW	3,051	2,824	8.0%	7.4%	0.6%
US	40	76	(47.3)%	(47.3)%	-
Intl	386	376	2.4%	1.1%	1.3%
WW	425	452	(5.9)%	(7.0)%	1.1%
US	104	119	(12.6)%	(12.6)%	-
Intl	602	684	(12.0)%	(14.5)%	2.5%
WW	706	803	(12.1)%	(14.2)%	2.1%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	THIRD QUARTER				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
<u>PULMONARY HYPERTENSION (PH)</u>					
US	\$ 588	815	(27.8)%	(27.8)%	-
Intl	309	300	2.9%	4.1%	(1.2)%
WW	897	1,115	(19.5)%	(19.2)%	(0.3)%
<u>UPTRAVI</u>					
US	383	392	(2.2)%	(2.2)%	-
Intl	100	92	8.9%	8.4%	0.5%
WW	483	484	(0.1)%	(0.2)%	0.1%
<u>OPSUMIT / OPSYNVI</u>					
US	193	409	(52.8)%	(52.8)%	-
Intl	179	168	5.9%	7.8%	(1.9)%
WW	372	578	(35.7)%	(35.2)%	(0.5)%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	12	13	(7.3)%	(7.3)%	-
Intl	30	39	(23.8)%	(21.2)%	(2.6)%
WW	42	53	(19.7)%	(17.7)%	(2.0)%
<u>INFECTIOUS DISEASES (ID)</u>					
US	317	326	(2.7)%	(2.7)%	-
Intl	496	501	(1.2)%	(0.1)%	(1.1)%
WW	813	829	(1.8)%	(1.1)%	(0.7)%
<u>EDURANT / rilpivirine</u>					
US	5	7	(31.6)%	(31.6)%	-
Intl	382	378	1.0%	2.4%	(1.4)%
WW	386	385	0.4%	1.8%	(1.4)%
<u>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</u>					
US	307	315	(2.5)%	(2.5)%	-
Intl	74	81	(8.9)%	(7.7)%	(1.2)%
WW	381	397	(3.8)%	(3.6)%	(0.2)%
<u>OTHER INFECTIOUS DISEASES</u>					
US	5	4	29.9%	29.9%	-
Intl	40	42	(6.2)%	(7.9)%	1.7%
WW	46	47	(3.0)%	(4.5)%	1.5%
<u>CARDIOVASCULAR / METABOLISM / OTHER (CVM)</u>					
US	736	750	(1.9)%	(1.9)%	-
Intl	112	149	(24.3)%	(23.8)%	(0.5)%
WW	849	899	(5.6)%	(5.5)%	(0.1)%
<u>XARELTO</u>					
US	653	635	2.7%	2.7%	-
Intl	-	-	-	-	-
WW	653	635	2.7%	2.7%	-
<u>OTHER</u>					
US	84	115	(27.2)%	(27.2)%	-
Intl	112	149	(24.3)%	(23.8)%	(0.5)%
WW	197	264	(25.5)%	(25.3)%	(0.2)%
<u>TOTAL PH, ID, CVM</u>					
US	1,643	1,891	(13.2)%	(13.2)%	-
Intl	917	950	(3.5)%	(2.5)%	(1.0)%
WW	2,560	2,843	(9.9)%	(9.6)%	(0.3)%
<u>TOTAL INNOVATIVE MEDICINE</u>					
US	10,447	9,402	11.1%	11.1%	-
Intl	6,310	6,161	2.4%	3.0%	(0.6)%
WW	\$ 16,757	15,563	7.7%	7.9%	(0.2)%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	NINE MONTHS				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
	\$ 2,233	2,358	(5.3)%	(5.3)%	-
	942	895	5.2%	2.9%	2.3%
	3,175	3,253	(2.4)%	(3.0)%	0.6%
	1,154	1,139	1.3%	1.3%	-
	306	272	12.7%	7.9%	4.8%
	1,460	1,411	3.5%	2.6%	0.9%
	1,042	1,175	(11.3)%	(11.3)%	-
	538	507	6.0%	4.4%	1.6%
	1,580	1,682	(6.1)%	(6.6)%	0.5%
	37	44	(15.5)%	(15.5)%	-
	98	116	(15.6)%	(15.3)%	(0.3)%
	135	160	(15.6)%	(15.4)%	(0.2)%
	959	961	(0.2)%	(0.2)%	-
	1,506	1,472	2.3%	(1.7)%	4.0%
	2,465	2,434	1.3%	(1.1)%	2.4%
	15	21	(30.1)%	(30.1)%	-
	1,131	1,082	4.5%	0.6%	3.9%
	1,145	1,103	3.8%	0.0%	3.8%
	937	932	0.6%	0.6%	-
	259	264	(1.9)%	(6.2)%	4.3%
	1,196	1,196	0.0%	(0.9)%	0.9%
	7	8	(11.4)%	(11.4)%	-
	116	126	(8.0)%	(11.7)%	3.7%
	124	135	(8.2)%	(11.7)%	3.5%
	2,235	2,381	(6.1)%	(6.1)%	-
	378	461	(17.9)%	(20.9)%	3.0%
	2,614	2,842	(8.0)%	(8.5)%	0.5%
	1,959	1,946	0.7%	0.7%	-
	-	-	-	-	-
	1,959	1,946	0.7%	0.7%	-
	276	435	(36.5)%	(36.5)%	-
	378	461	(17.9)%	(20.9)%	3.0%
	655	896	(26.9)%	(28.5)%	1.6%
	5,428	5,700	(4.8)%	(4.8)%	-
	2,826	2,828	(0.1)%	(3.4)%	3.3%
	8,254	8,529	(3.2)%	(4.3)%	1.1%
	29,297	26,655	9.9%	9.9%	-
	19,270	17,983	7.2%	3.6%	3.6%
	\$ 48,567	44,638	8.8%	7.4%	1.4%

MEDTECH SEGMENT ⁽²⁾

CARDIOVASCULAR

US	\$	1,397	1,306	7.0%	7.0%	-
Intl		910	908	0.2%	(0.2)%	0.4%
WW		2,307	2,213	4.3%	4.1%	0.2%

ELECTROPHYSIOLOGY

US		771	720	7.0%	7.0%	-
Intl		717	698	2.8%	1.8%	1.0%
WW		1,487	1,418	4.9%	4.4%	0.5%

ABIOMED

US		335	336	(0.3)%	(0.3)%	-
Intl		78	86	(10.4)%	(6.5)%	(3.9)%
WW		412	423	(2.3)%	(1.5)%	(0.8)%

SHOCKWAVE

US		261	220	18.8%	18.8%	-
Intl		64	59	9.3%	11.2%	(1.9)%
WW		325	278	16.8%	17.2%	(0.4)%

OTHER CARDIOVASCULAR

US		31	30	3.6%	3.6%	-
Intl		50	65	(21.9)%	(23.1)%	1.2%
WW		81	95	(13.9)%	(14.7)%	0.8%

SURGERY

US		1,070	1,031	3.7%	3.7%	-
Intl		1,459	1,511	(3.4)%	(4.2)%	0.8%
WW		2,528	2,542	(0.6)%	(1.0)%	0.4%

ADVANCED

US		500	477	5.1%	5.1%	-
Intl		654	688	(5.0)%	(5.7)%	0.7%
WW		1,155	1,165	(0.9)%	(1.3)%	0.4%

GENERAL

US		568	555	2.4%	2.4%	-
Intl		805	823	(2.2)%	(3.0)%	0.8%
WW		1,373	1,378	(0.3)%	(0.8)%	0.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

NINE MONTHS					
2026	2025	% Change		Currency	
		Reported	Operational ⁽¹⁾		
\$	4,222	3,931	7.4%	7.4%	-
	2,866	2,698	6.2%	3.4%	2.8%
	7,088	6,629	6.9%	5.8%	1.1%
	2,290	2,145	6.8%	6.8%	-
	2,219	2,064	7.5%	4.3%	3.2%
	4,509	4,209	7.1%	5.6%	1.5%
	1,066	1,035	3.0%	3.0%	-
	275	256	7.2%	5.4%	1.8%
	1,340	1,291	3.8%	3.5%	0.3%
	771	659	17.0%	17.0%	-
	194	169	14.8%	15.1%	(0.3)%
	965	828	16.6%	16.6%	0.0%
	96	93	3.2%	3.2%	-
	177	209	(15.0)%	(17.7)%	2.7%
	273	302	(9.4)%	(11.3)%	1.9%
	3,210	3,076	4.3%	4.3%	-
	4,483	4,417	1.5%	(1.6)%	3.1%
	7,692	7,493	2.7%	0.8%	1.9%
	1,476	1,411	4.7%	4.7%	-
	1,991	1,991	0.0%	(2.9)%	2.9%
	3,467	3,402	1.9%	0.2%	1.7%
	1,733	1,666	4.0%	4.0%	-
	2,492	2,426	2.7%	(0.6)%	3.3%
	4,225	4,092	3.3%	1.3%	2.0%

See footnotes at end of schedule

VISION

US
Intl
WW

CONTACT LENSES / OTHER

US
Intl
WW

SURGICAL

US
Intl
WW

ORTHOPAEDICS

US
Intl
WW

HIPS

US
Intl
WW

KNEES

US
Intl
WW

TRAUMA

US
Intl
WW

SPINE, SPORTS & OTHER

US
Intl
WW

TOTAL MEDTECH

US
Intl
WW

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
THIRD QUARTER					
	2026	2025	Reported	% Change Operational ⁽¹⁾	Currency
US	\$ 596	571	4.3%	4.3%	-
Intl	865	828	4.4%	5.6%	(1.2)%
WW	1,461	1,400	4.4%	5.1%	(0.7)%
CONTACT LENSES / OTHER					
US	465	456	1.9%	1.9%	-
Intl	588	562	4.7%	6.2%	(1.5)%
WW	1,053	1,018	3.5%	4.3%	(0.8)%
SURGICAL					
US	132	116	13.6%	13.6%	-
Intl	276	266	3.8%	4.3%	(0.5)%
WW	408	383	6.8%	7.1%	(0.3)%
ORTHOPAEDICS					
US	1,448	1,396	3.8%	3.8%	-
Intl	898	878	2.2%	2.9%	(0.7)%
WW	2,345	2,274	3.2%	3.4%	(0.2)%
HIPS					
US	271	262	3.5%	3.5%	-
Intl	148	144	2.6%	3.0%	(0.4)%
WW	419	405	3.1%	3.3%	(0.2)%
KNEES					
US	221	216	2.1%	2.1%	-
Intl	165	160	3.0%	4.4%	(1.4)%
WW	386	377	2.5%	3.1%	(0.6)%
TRAUMA					
US	555	512	8.6%	8.6%	-
Intl	288	281	2.4%	2.8%	(0.4)%
WW	844	793	6.4%	6.5%	(0.1)%
SPINE, SPORTS & OTHER					
US	401	406	(1.2)%	(1.2)%	-
Intl	296	293	1.3%	2.0%	(0.7)%
WW	697	698	(0.1)%	0.1%	(0.2)%
TOTAL MEDTECH					
US	4,512	4,306	4.8%	4.8%	-
Intl	4,130	4,124	0.1%	0.1%	0.0%
WW	\$ 8,642	8,430	2.5%	2.5%	0.0%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

NINE MONTHS					
	2026	2025	Reported	% Change Operational ⁽¹⁾	Currency
US	\$ 1,740	1,694	2.7%	2.7%	-
Intl	2,537	2,354	7.8%	6.3%	1.5%
WW	4,277	4,048	5.6%	4.8%	0.8%
CONTACT LENSES / OTHER					
US	1,378	1,337	3.1%	3.1%	-
Intl	1,669	1,565	6.6%	5.5%	1.1%
WW	3,047	2,902	5.0%	4.4%	0.6%
SURGICAL					
US	363	358	1.4%	1.4%	-
Intl	867	789	10.0%	8.0%	2.0%
WW	1,230	1,147	7.3%	5.9%	1.4%
ORTHOPAEDICS					
US	4,353	4,200	3.6%	3.6%	-
Intl	2,794	2,620	6.6%	3.5%	3.1%
WW	7,146	6,820	4.8%	3.6%	1.2%
HIPS					
US	831	796	4.4%	4.4%	-
Intl	465	440	5.7%	2.1%	3.6%
WW	1,296	1,235	4.9%	3.6%	1.3%
KNEES					
US	688	673	2.2%	2.2%	-
Intl	528	482	9.7%	7.1%	2.6%
WW	1,216	1,155	5.3%	4.2%	1.1%
TRAUMA					
US	1,623	1,515	7.1%	7.1%	-
Intl	880	818	7.6%	4.4%	3.2%
WW	2,504	2,333	7.3%	6.2%	1.1%
SPINE, SPORTS & OTHER					
US	1,211	1,216	(0.4)%	(0.4)%	-
Intl	920	881	4.5%	1.5%	3.0%
WW	2,131	2,096	1.7%	0.4%	1.3%
TOTAL MEDTECH					
US	13,525	12,902	4.8%	4.8%	-
Intl	12,679	12,089	4.9%	2.2%	2.7%
WW	\$ 26,204	24,991	4.9%	3.5%	1.4%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

- * Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
THIRD QUARTER

	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 25,399	100.0	\$ 23,993	100.0	5.9
Cost of products sold	8,097	31.9	7,303	30.4	10.9
Gross Profit	17,302	68.1	16,690	69.6	3.7
Selling, marketing and administrative expenses	6,285	24.7	5,922	24.7	6.1
Research and development expense	4,652	18.3	3,672	15.3	26.7
In-process research and development impairments	339	1.4	-	-	
Interest (income) expense, net	31	0.1	18	0.1	
Other (income) expense, net	5,780	22.8	(478)	(2.0)	
Restructuring	181	0.7	63	0.3	
Earnings before provision for taxes on income	34	0.1	7,493	31.2	(99.5)
(Benefit from)/Provision for taxes on income	(176)	(0.7)	2,341	9.7	(107.5)
Net earnings	\$ 210	0.8	\$ 5,152	21.5	(95.9)
Net earnings per share (Diluted)	\$ 0.09		\$ 2.12		(95.8)
Average shares outstanding (Diluted)	2,448.6		2,428.6		
Effective tax rate	(517.6) %		31.2 %		

Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 7,672	30.2	\$ 8,436	35.2	(9.1)
Net earnings	\$ 6,339	25.0	\$ 6,801	28.3	(6.8)
Net earnings per share (Diluted)	\$ 2.59		\$ 2.80		(7.5)
Effective tax rate	17.4 %		19.4 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS

	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 74,771	100.0	\$ 69,629	100.0	7.4
Cost of products sold	24,254	32.4	22,288	32.0	8.8
Gross Profit	50,517	67.6	47,341	68.0	6.7
Selling, marketing and administrative expenses	18,751	25.1	16,923	24.3	10.8
Research and development expense	11,832	15.8	10,413	15.0	13.6
In-process research and development impairments	375	0.5	-	-	
Interest (income) expense, net	136	0.2	(62)	(0.1)	
Other (income) expense, net	6,405	8.6	(7,692)	(11.1)	
Restructuring	247	0.3	144	0.2	
Earnings before provision for taxes on income	12,771	17.1	27,615	39.7	(53.8)
Provision for taxes on income	1,792	2.4	5,927	8.6	(69.8)
Net earnings	\$ 10,979	14.7	\$ 21,688	31.1	(49.4)
Net earnings per share (Diluted)	\$ 4.49		\$ 8.94		(49.8)
Average shares outstanding (Diluted)	2,445.8		2,424.8		
Effective tax rate	14.0 %		21.5 %		
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 24,153	32.3	\$ 24,635	35.4	(2.0)
Net earnings	\$ 20,034	26.8	\$ 20,206	29.0	(0.9)
Net earnings per share (Diluted)	\$ 8.19		\$ 8.33		(1.7)
Effective tax rate	17.1 %		18.0 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
THIRD QUARTER 2026 ACTUAL vs. 2025 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	7.7%	2.5%	5.9%
U.S.	11.1%	4.8%	9.1%
International	2.4%	0.1%	1.5%
WW Currency	(0.2)	0.0	(0.1)
U.S.	-	-	-
International	(0.6)	0.0	(0.3)
WW Operational	7.9%	2.5%	6.0%
U.S.	11.1%	4.8%	9.1%
International	3.0%	0.1%	1.8%
WW Adjusted Operational Ex A&D	8.0%	2.5%	6.1%
U.S.	11.1%	4.8%	9.1%
International	3.2%	0.1%	1.9%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
NINE MONTHS 2026 ACTUAL vs. 2025 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	8.8%	4.9%	7.4%
U.S.	9.9%	4.8%	8.3%
International	7.2%	4.9%	6.2%
WW Currency	1.4	1.4	1.4
U.S.	-	-	-
International	3.6	2.7	3.2
WW Operational	7.4%	3.5%	6.0%
U.S.	9.9%	4.8%	8.3%
International	3.6%	2.2%	3.0%
Caplyta	(0.6)		(0.4)
U.S.	(1.0)		(0.7)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.1	0.1	0.1
U.S.	0.0	0.1	0.0
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	6.9%	3.6%	5.7%
U.S.	8.9%	4.9%	7.6%
International	3.8%	2.2%	3.1%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Third Quarter		Nine Months Ended	
(Dollars in Millions Except Per Share Data)	2026	2025	2026	2025
Net Earnings, after tax- as reported	\$210	\$5,152	\$10,979	\$21,688
<i>Pre-tax Adjustments</i>				
Litigation related	5,519	15	6,116	(6,894)
Intangible Asset Amortization expense	1,240	1,048	3,732	3,435
Restructuring related ¹	195	168	533	302
Orthopaedics separation related	369	-	746	-
Acquisition, integration and divestiture related	(34)	97	142	475
(Gains)/losses on securities	10	(387)	(262)	(327)
IPR&D impairments	339	-	375	-
Other	-	2	-	29
<i>Tax Adjustments</i>				
Tax impact on special item adjustments ²	(1,677)	(168)	(2,469)	826
Tax legislation and other tax related	168	874	142	672
Adjusted Net Earnings , after tax	\$6,339	\$6,801	\$20,034	\$20,206
Average shares outstanding (Diluted)	2,448.6	2,428.6	2,445.8	2,424.8
Adjusted net earnings per share (Diluted)	\$2.59	\$2.80	\$8.19	\$8.33
Operational adjusted net earnings per share (Diluted)	\$2.61		\$8.04	

Notes:

¹ In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between \$650 - \$750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of \$74 million in the fiscal third quarter of 2026 (\$274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of \$80 million were recorded in the fiscal third quarter of 2026 (\$194 million Q3 2026 YTD) and \$128 million in the fiscal third quarter of 2025 (\$157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of \$41 million in the fiscal third quarter of 2026 (\$65 million Q3 2026 YTD) and \$40 million in the fiscal third quarter of 2025 (\$145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately \$1 billion.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

	Third Quarter September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Third Quarter September 27, 2026 Non-GAAP
Innovative Medicine										
Cost of products sold	\$ 4,486	(762)			18	(2)				3,740
Selling, marketing and admin expenses	3,035									3,035
Research and development expense	3,888									3,888
Other segment items	282		24		(92)	(53)	4			165
Adjusted Income Before Tax by Segment	5,066	762	(24)	-	74	55	(4)	-	-	5,929
	Third Quarter September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Third Quarter September 27, 2026 Non-GAAP
MedTech										
Cost of products sold	\$ 3,597	(478)			(13)			(6)		3,100
Selling, marketing and admin expenses	3,014							(38)		2,976
Research and development expense	764							(5)		759
Other segment items	491		22	(339)	(108)	95	(14)	(320)		(173)
Adjusted Income Before Tax by Segment	776	478	(22)	339	121	(95)	14	369	-	1,980
	Third Quarter September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Third Quarter September 27, 2026 Non-GAAP
Expenses not allocated to segments										
Cost of products sold	\$ 14									14
Selling, marketing and admin expenses	236									236
Research and development expense	-									-
Other segment items	5,558		(5,565)			(6)				(13)
Adjusted Income Before Tax by Segment	(5,808)	-	5,565	-	-	6	-	-	-	(237)
	Third Quarter September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Third Quarter September 27, 2026 Non-GAAP
Johnson & Johnson Consolidated										
Cost of products sold	\$ 8,097	(1,240)			5	(2)		(6)		6,854
Selling, marketing and admin expenses	6,285							(38)		6,247
Research and development expense	4,652							(5)		4,647
Other (Income) / Expense	5,780		(5,519)		(19)	36	(10)	(320)		(52)
In-process research and development impairments	339			(339)						-
Interest (Income)/Expense	31									31
Restructuring	181				(181)					-
Adjusted Income Before Tax	34	1,240	5,519	339	195	(34)	10	369	-	7,672
(Benefit from)/Provision for taxes on income	(176)	239	1,230	85	37	18	-	68	(168)	1,333
Net Earnings	210	1,001	4,289	254	158	(52)	10	301	168	6,339

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

Innovative Medicine

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Third Quarter Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Third Quarter Sept 28, 2025 Non-GAAP
\$ 3,672	(568)			(11)				3,093
2,869								2,869
2,944								2,944
(368)		5		(48)	174		(1)	(238)
6,446	568	(5)	-	59	(174)	-	1	6,895

MedTech

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Third Quarter Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Third Quarter Sept 28, 2025 Non-GAAP
\$ 3,612	(480)		(12)	(1)				3,119
2,801								2,801
728								728
2		5	(156)	(48)	213		(1)	15
1,287	480	(5)	168	49	(213)	-	1	1,767

Expenses not allocated to segments

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Third Quarter Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Third Quarter Sept 28, 2025 Non-GAAP
\$ 19								19
252								252
-								-
(31)		(25)		11				(45)
(240)	-	25	-	(11)	-	-	-	(226)

Johnson & Johnson Consolidated

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other (Income) / Expense
In-process research and development impairments
Interest (Income)/Expense
Restructuring
Adjusted Income Before Tax
Provision for taxes on income
Net Earnings

Third Quarter Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Third Quarter Sept 28, 2025 Non-GAAP
\$ 7,303	(1,048)		(12)	(12)				6,231
5,922								5,922
3,672								3,672
(478)		(15)	(93)	(85)	387		(2)	(286)
-								-
18								18
63			(63)					-
7,493	1,048	15	168	97	(387)	-	2	8,436
2,341	193	3	34	16	(87)	(874)	9	1,635
5,152	855	12	134	81	(300)	874	(7)	6,801

Year to Date

Innovative Medicine

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation \$ in Millions									
Nine Months September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Nine Months September 27, 2026 Non-GAAP
\$ 13,172	(2,289)				(21)				10,862
9,083									9,083
9,576									9,576
104		75		(274)	(153)	286			38
16,632	2,289	(75)	-	274	174	(286)	-	-	19,008

MedTech

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Nine Months September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Nine Months September 27, 2026 Non-GAAP
\$ 11,035	(1,443)			(55)			(9)		9,528
8,989							(55)		8,934
2,256							(7)		2,249
732		139	(375)	(204)	31	(24)	(675)		(376)
3,192	1,443	(139)	375	259	(31)	24	746	-	5,869

Expenses not allocated to segments

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Nine Months September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Nine Months September 27, 2026 Non-GAAP
\$ 47									47
679									679
-									-
6,327		(6,330)			1				(2)
(7,053)	-	6,330	-	-	(1)	-	-	-	(724)

Johnson & Johnson Consolidated

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other (Income) / Expense
In-process research and development impairments
Interest (Income)/Expense
Restructuring
Adjusted Income Before Tax
Provision for taxes on income
Net Earnings

Nine Months September 27, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Nine Months September 27, 2026 Non-GAAP
\$ 24,254	(3,732)			(55)	(21)		(9)		20,437
18,751							(55)		18,696
11,832							(7)		11,825
6,405		(6,116)		(231)	(121)	262	(675)		(476)
375			(375)						-
136									136
247				(247)					-
12,771	3,732	6,116	375	533	142	(262)	746	-	24,153
1,792	718	1,361	93	161	63	(63)	136	(142)	4,119
10,979	3,014	4,755	282	372	79	(199)	610	142	20,034

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	Nine Months Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Nine Months Sept 28, 2025 Non-GAAP
Innovative Medicine									
Cost of products sold	\$ 11,670	(2,002)			(24)				9,644
Selling, marketing and admin expenses	7,919								7,919
Research and development expense	8,361								8,361
Other segment items	(520)		74		(275)	164		(14)	(571)
Adjusted Income Before Tax by Segment	17,208	2,002	(74)	-	299	(164)	-	14	19,285

	Nine Months Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Nine Months Sept 28, 2025 Non-GAAP
MedTech									
Cost of products sold	\$ 10,576	(1,433)		(35)	(52)				9,056
Selling, marketing and admin expenses	8,319								8,319
Research and development expense	2,052				37				2,089
Other segment items	132		(78)	(267)	(155)	163		(15)	(220)
Adjusted Income Before Tax by Segment	3,912	1,433	78	302	170	(163)	-	15	5,747

	Nine Months Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Nine Months Sept 28, 2025 Non-GAAP
Expenses not allocated to segments									
Cost of products sold	\$ 42								42
Selling, marketing and admin expenses	685								685
Research and development expense									-
Other segment items	(7,222)		6,898		(6)				(330)
Adjusted Income Before Tax by Segment	6,495	-	(6,898)	-	6	-	-	-	(397)

	Nine Months Sept 28, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Nine Months Sept 28, 2025 Non-GAAP
Johnson & Johnson Consolidated									
Cost of products sold	\$ 22,288	(3,435)		(35)	(76)				18,742
Selling, marketing and admin expenses	16,923								16,923
Research and development expense	10,413				37				10,450
Other (Income) / Expense	(7,692)		6,894	(123)	(436)	327		(29)	(1,059)
In-process research and development impairments	-								-
Interest (Income)/Expense	(62)								(62)
Restructuring	144			(144)					-
Adjusted Income Before Tax	27,615	3,435	(6,894)	302	475	(327)	-	29	24,635
Provision for taxes on income	5,927	603	(1,541)	58	118	(73)	(672)	9	4,429
Net Earnings	21,688	2,832	(5,353)	244	357	(254)	672	20	20,206